| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Vijaya Kumar, Lavanya Sharma, Srikanth Madival, Ganesan Venkatasubramania. Successful management of clozapine adverse effects with extended (alternate day) antipsychotic dosing in a patient with schizophrenia. Journal of psychiatry & neuroscience : JPN. vol 41. issue 1. 2017-01-04. PMID:26674512. |
successful management of clozapine adverse effects with extended (alternate day) antipsychotic dosing in a patient with schizophrenia. |
2017-01-04 |
2023-08-13 |
Not clear |
| Leslie Citrome, Joseph P McEvoy, Stephen R Sakla. Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. Clinical schizophrenia & related psychoses. vol 10. issue 3. 2017-01-03. PMID:27732102. |
clozapine is a highly effective antipsychotic medication, which provides a range of significant benefits for patients with schizophrenia, and is the standard of care for treatment-resistant schizophrenia as well as for reducing the risk of suicidal behaviors in schizophrenia and schizoaffective disorder. |
2017-01-03 |
2023-08-13 |
Not clear |
| Oddur Ingimarsson, James H MacCabe, Magnús Haraldsson, Halldóra Jónsdóttir, Engilbert Sigurdsso. Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records. Nordic journal of psychiatry. vol 70. issue 6. 2016-12-16. PMID:27049594. |
clozapine is the only drug approved for treatment-resistant schizophrenia. |
2016-12-16 |
2023-08-13 |
Not clear |
| Varun Monga, Marin Broucek, Mojgan Amani, Sriram Ramaswam. Clozapine and concomitant chemotherapy in a patient with schizophrenia and new onset esophageal cancer. Psycho-oncology. vol 24. issue 8. 2016-12-13. PMID:25644505. |
clozapine and concomitant chemotherapy in a patient with schizophrenia and new onset esophageal cancer. |
2016-12-13 |
2023-08-13 |
Not clear |
| Ting-She Chang, Chia-Kuang Tsai, Chih-Sung Lian. Clozapine use in refractory schizophrenia comorbid with acute myeloid leukemia. Psychosomatics. vol 56. issue 3. 2016-12-13. PMID:25886972. |
clozapine use in refractory schizophrenia comorbid with acute myeloid leukemia. |
2016-12-13 |
2023-08-13 |
Not clear |
| John Lally, John Tully, Dene Robertson, Brendon Stubbs, Fiona Gaughran, James H MacCab. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. Schizophrenia research. vol 171. issue 1-3. 2016-12-13. PMID:26827129. |
augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis. |
2016-12-13 |
2023-08-13 |
Not clear |
| John Lally, John Tully, Dene Robertson, Brendon Stubbs, Fiona Gaughran, James H MacCab. Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis. Schizophrenia research. vol 171. issue 1-3. 2016-12-13. PMID:26827129. |
the primary aim of this systematic review and meta-analysis was to assess the proportion of patients with treatment resistant schizophrenia (trs) that respond to ect augmentation of clozapine (c+ect). |
2016-12-13 |
2023-08-13 |
Not clear |
| Carla Comacchio, Nicola Dusi, Antonio Lasalvi. Successful Use of Single Doses of Granulocyte-Colony Stimulating Factor (G-CSF) in the Treatment of Late-Onset Agranulocytosis Associated With Clozapine in a Patient With Treatment-Resistant Schizophrenia: A Case Report. Journal of clinical psychopharmacology. vol 36. issue 2. 2016-12-13. PMID:26859277. |
successful use of single doses of granulocyte-colony stimulating factor (g-csf) in the treatment of late-onset agranulocytosis associated with clozapine in a patient with treatment-resistant schizophrenia: a case report. |
2016-12-13 |
2023-08-13 |
Not clear |
| Peter F J Schulte, Johanna T H Bocxe, Hieronymus J Doodeman, Ingrid M M van Haelst, Dan Cohe. Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 36. issue 2. 2016-12-13. PMID:26872114. |
risk of new-onset diabetes after long-term treatment with clozapine in comparison to other antipsychotics in patients with schizophrenia. |
2016-12-13 |
2023-08-13 |
Not clear |
| Peter F J Schulte, Johanna T H Bocxe, Hieronymus J Doodeman, Ingrid M M van Haelst, Dan Cohe. Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 36. issue 2. 2016-12-13. PMID:26872114. |
to confirm these findings, we examined retrospectively the risk of new-onset diabetes in long-term clozapine treatment compared to treatment with other antipsychotics in a matched control population with schizophrenia or schizoaffective disorder. |
2016-12-13 |
2023-08-13 |
Not clear |
| Peter F J Schulte, Johanna T H Bocxe, Hieronymus J Doodeman, Ingrid M M van Haelst, Dan Cohe. Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 36. issue 2. 2016-12-13. PMID:26872114. |
ninety-four adult patients with schizophrenia or schizoaffective disorder who had been treated with clozapine for 5 years or longer were matched on age, diagnosis, and sex to 94 patients without any use of clozapine. |
2016-12-13 |
2023-08-13 |
Not clear |
| Jan P A M Bogers, Peter F J Schulte, Daniel Van Dijk, Bert Bakker, Dan Cohe. Clozapine Underutilization in the Treatment of Schizophrenia: How Can Clozapine Prescription Rates Be Improved? Journal of clinical psychopharmacology. vol 36. issue 2. 2016-12-13. PMID:26872120. |
clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates be improved? |
2016-12-13 |
2023-08-13 |
Not clear |
| Danielle L Taylor, Arun K Tiwari, Jeffrey A Lieberman, Steven G Potkin, Herbert Y Meltzer, Jo Knight, Gary Remington, Daniel J Müller, James L Kenned. Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine. Human psychopharmacology. vol 31. issue 2. 2016-12-13. PMID:26876050. |
clozapine is the most efficacious drug for treatment-resistant schizophrenia and may deliver superior therapeutic effects partly by modulating glutamate neurotransmission. |
2016-12-13 |
2023-08-13 |
Not clear |
| Jimmi Nielsen, Corina Young, Petru Ifteni, Taishiro Kishimoto, Yu-Tao Xiang, Peter F J Schulte, Christoph U Correll, David Taylo. Worldwide Differences in Regulations of Clozapine Use. CNS drugs. vol 30. issue 2. 2016-12-13. PMID:26884144. |
clozapine remains the drug of choice for treatment-resistant schizophrenia. |
2016-12-13 |
2023-08-13 |
Not clear |
| Mark Olfson, Tobias Gerhard, Stephen Crystal, T Scott Strou. Clozapine for Schizophrenia: State Variation in Evidence-Based Practice. Psychiatric services (Washington, D.C.). vol 67. issue 2. 2016-11-01. PMID:26522679. |
clozapine for schizophrenia: state variation in evidence-based practice. |
2016-11-01 |
2023-08-13 |
Not clear |
| Jimmy Lee, Hiroyoshi Takeuchi, Gagan Fervaha, Gwen Li Sin, George Foussias, Ofer Agid, Saeed Farooq, Gary Remingto. Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 60. issue 11. 2016-10-05. PMID:26720509. |
evidence suggests that aps, both old and new, are comparable in terms of efficacy; however, one ap, clozapine, is uniquely effective in one subgroup of patients (that is, those with treatment-resistant schizophrenia [trs]). |
2016-10-05 |
2023-08-13 |
Not clear |
| Jimmy Lee, Hiroyoshi Takeuchi, Gagan Fervaha, Gwen Li Sin, George Foussias, Ofer Agid, Saeed Farooq, Gary Remingto. Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 60. issue 11. 2016-10-05. PMID:26720509. |
this permits us to subdivide schizophrenia into 3 specific groups: ap responsive, clozapine responsive, and clozapine resistant. |
2016-10-05 |
2023-08-13 |
Not clear |
| Eric Huang, Malgorzata Maciukiewicz, Clement C Zai, Arun K Tiwari, Jiang Li, Steven G Potkin, Jeffrey A Lieberman, Herbert Y Meltzer, Daniel J Müller, James L Kenned. Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. Pharmacogenomics. vol 17. issue 2. 2016-09-15. PMID:26666695. |
preliminary evidence for association of genome-wide significant drd2 schizophrenia risk variant with clozapine response. |
2016-09-15 |
2023-08-13 |
Not clear |
| Narjes Hendouei, Seyed Hamzeh Hosseini, Amin Panahi, Zahra Khazaeipour, Fatemeh Barari, Adeleh Sahebnasagh, Shahram Al. Negative Correlation between Serum S100B and Leptin Levels in Schizophrenic Patients During Treatment with Clozapine and Risperidone: Preliminary Evidence. Iranian journal of pharmaceutical research : IJPR. vol 15. issue 1. 2016-09-09. PMID:27610173. |
in this study we evaluated the relationship between s100b and leptin in schizophrenic patients under treatment with clozapine and risperidone.this study included 19 patients meeting the dsm-iv-tr criteria for schizophrenia, having body mass index (bmi) of 16- 25 kg/m(2) and suffering schizophrenia for more than 3 years and from this study. |
2016-09-09 |
2023-08-13 |
Not clear |
| Sefa Vayısoğlu, Elif Anıl Yağcıoğl. [Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 25. issue 3. 2016-09-06. PMID:25219694. |
[augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment]. |
2016-09-06 |
2023-08-13 |
Not clear |